Unit of Social Pediatrics, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Ann Hematol. 2010 Sep;89(9):913-8. doi: 10.1007/s00277-009-0897-1. Epub 2010 Jan 30.
Vaccination is the best strategy to prevent influenza infection that is a potential cause of morbidity and mortality in immunosuppressed patients. Here, we evaluated the factors that may affect serological response to influenza vaccine in patients who have undergone hematopoetic stem cell transplantation (HSCT). Sixty-one HSCT recipients were included in the study during the 2007-2008 influenza season. Serum samples prior to vaccination and 6-10 weeks after vaccination were collected. Samples were assayed for antibodies to influenza virus A/H1N1, A/H3N2, and B strains by hemagglutination-inhibition assay. The patients were followed in terms of clinical symptoms up to the next influenza season and for adverse effects within a month after vaccination. Overall, pre-vaccine seroprotection rate against all vaccine antigens (A/H1N1, A/H3N2, and B antigens) was 45.1%, post-vaccine seroprotection rate 91% and seroconversion rate was 28.3%. Seroconversion rates were found to be low against B in patients who were vaccinated in the late influenza season (p = 0.018; respectively). Five patients (10.9%) had no immune response against H1N1. Adverse events were reported in 19.6% (n = 9/46) of the patients. In conclusion, the patients should be vaccinated as early as possible in the influenza season, before they are exposed to the virus.
接种疫苗是预防流感感染的最佳策略，流感感染可能是免疫抑制患者发病和死亡的潜在原因。在此，我们评估了可能影响造血干细胞移植（HSCT）患者对流感疫苗血清学反应的因素。在 2007-2008 流感季节，我们纳入了 61 例 HSCT 受者进行研究。在接种疫苗前和接种后 6-10 周采集血清样本。采用血凝抑制试验检测血清中针对甲型流感病毒 H1N1、H3N2 和 B 株的抗体。我们随访患者至下一个流感季节，观察临床症状，并在接种后 1 个月内观察不良事件。总体而言，所有疫苗抗原（甲型流感病毒 H1N1、H3N2 和 B 抗原）的疫苗接种前血清保护率为 45.1%，疫苗接种后血清保护率为 91%，血清转化率为 28.3%。在流感季节晚期接种疫苗的患者中，B 型血清转化率较低（p = 0.018）。5 例患者（10.9%）对 H1N1 无免疫反应。19.6%（n = 9/46）的患者报告了不良事件。总之，患者应在流感季节尽早接种疫苗，以避免接触病毒。
